Lisinopril
Zestril, Prinivil
Also known as: Glucotrol
Sulfonylurea. Causes glucose-independent insulin secretion and therefore hypoglycaemia during the treatment fast. Shorter-acting than glyburide, which lowers but does not remove the risk.
Severity
Major risk
Mechanism
Other clinical interaction
Protocol Status
Hold on the fasting and treatment day — the prescription stays with your physician
Restart Delay
Physician discretion
What "Major risk" Means
Serious clinical risk requiring physician-led tapering, washout, and monitoring. Treatment may proceed once the medication is appropriately cleared or transitioned.
Clinical Action
Hold on the fasting and treatment day. Check glucose q4h through the fast and acute phase. Resume when eating reliably.
Where the Washout Happens
Hold on the fasting and treatment day — the prescription stays with your physician
The medication is continued right up to arrival — its condition is managed by your prescribing physician and is not stopped on our initiative — but it is HELD on the fasting and treatment day, because it lowers blood sugar while the patient is fasting and often vomiting, which is when hypoglycaemia becomes dangerous. Blood glucose is checked at least every four hours through the fast and the acute phase, dextrose is kept immediately available, and the dose resumes once the patient is eating reliably. Any change to the prescription belongs to the prescribing physician.
Post-Treatment Restart
Restart at physician discretion once acute window closes.
The Pharmacology
This class has clinical considerations that do not fit a single mechanism category. Review the specific risk and clinical action for handling, and discuss with the prescribing physician.
Same Mechanism
Same Severity Tier
Opioid receptor potentiation
Methadose, Dolophine
Opioid receptor potentiation
Suboxone, Subutex
Opioid receptor potentiation
Duragesic, Sublimaze
Opioid receptor potentiation
Oxycontin, Percocet
Opioid receptor potentiation
Vicodin, Norco
Opioid receptor potentiation
Ms Contin, Kadian
Common Questions
Major risk. Sulfonylurea. Causes glucose-independent insulin secretion and therefore hypoglycaemia during the treatment fast. Shorter-acting than glyburide, which lowers but does not remove the risk. Hold on the fasting and treatment day. Check glucose q4h through the fast and acute phase. Resume when eating reliably.
Hold on the fasting and treatment day — the prescription stays with your physician. The medication is continued right up to arrival — its condition is managed by your prescribing physician and is not stopped on our initiative — but it is HELD on the fasting and treatment day, because it lowers blood sugar while the patient is fasting and often vomiting, which is when hypoglycaemia becomes dangerous. Blood glucose is checked at least every four hours through the fast and the acute phase, dextrose is kept immediately available, and the dose resumes once the patient is eating reliably. Any change to the prescription belongs to the prescribing physician.
Other clinical interaction. This class has clinical considerations that do not fit a single mechanism category. Review the specific risk and clinical action for handling, and discuss with the prescribing physician.
In many cases yes. Our medical team works with your prescribing physician to taper or substitute medications safely before treatment. The right substitution depends on the underlying condition you are treating with Glipizide — contact us for an individual review.
Checking more than one medication? Use the interactive Drug Interaction Checker to screen your full medication list at once.
Browse all 174 medications in the A–Z directory.